Rapamycin Holdings, based in San Antonio, TX, is a biotechnology company focused on commercializing eRapa, a targeted formulation of rapamycin, for the prevention and treatment of rare genetic diseases and cancer. Their innovative pipeline includes early-stage cancers, precancerous conditions, and aging-related diseases.
eRapa, a novel formulation of rapamycin developed by Rapamycin Holdings, has shown promise in extending life by delaying the onset of aging-related diseases and mitigating the effects of normal aging. The company's leading indications include non-muscle invasive bladder cancer, low-grade prostate cancer, and Familial Adenomatous Polyposis (FAP), a rare genetic disease associated with colon cancer for which current therapeutics are limited.
Generated from the website